Formation of co-crystals: Kinetic and thermodynamic aspects

被引:93
作者
Gagniere, E. [1 ]
Mangin, D. [1 ]
Puel, F. [1 ]
Rivoire, A. [2 ]
Monnier, O. [3 ]
Garcia, E. [4 ]
Klein, J. R. [1 ]
机构
[1] Univ Lyon 1, LAGEP, UMR CNRS CPE 5007, F-69622 Villeurbanne, France
[2] CPE Lyon, F-69616 Villeurbanne, France
[3] SANOFI AVENTIS Rech, F-34000 Montpellier, France
[4] SANOFI AVENTIS Chim, F-30390 Aramon, France
关键词
Nucleation; Phase diagram; Growth from solutions; Industrial crystallisation; Organic compounds; Cocrystals; ACID;
D O I
10.1016/j.jcrysgro.2009.02.040
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
Co-crystallisation is a recent method of great interest for the pharmaceutical industry, since pharmaceutical co-crystals represent useful materials for drug products. In this study, an active pharmaceutical ingredient (carbamazepine (CBZ)) co-crystallized with a vitamin (nicotinamide (NCT)) was chosen as a model substance. This work was focused on the construction of a phase diagram for the system CBZ/NCT, split in six domains for kinetic reasons (the different solid phases which might appear during the crystallisation) and in four domains according to thermodynamic aspects (the stable final phase obtained). Although co-crystals are not ionic compounds, the supersaturation of co-crystals can be evaluated by considering the solubility product. Batch crystallisation operations were carried out in a stirred vessel equipped with an in situ video probe. This latter device was a powerful analysis tool to monitor the CBZ/NCT co-crystals and single CBZ crystals since these two crystalline phases grown in ethanol exhibited needle and platelet habits. As concerns kinetics, the different solid phases which might appear during the experiments were observed and competed against each others. In accordance with thermodynamics, the stable solid form was obtained at the end of the operation. Finally some preliminary results indicate that the nucleation of co-crystals may be favoured by the presence of CBZ crystals. Epitaxial relationships between CBZ/NCT co-crystals and CBZ crystals were suspected. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:2689 / 2695
页数:7
相关论文
共 10 条
[1]   Building co-crystals with molecular sense and supramolecular sensibility [J].
Aakeröy, CB ;
Salmon, DJ .
CRYSTENGCOMM, 2005, 7 :439-448
[2]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[3]   PHASE-TRANSITION AND EPITAXIES BETWEEN HYDRATED ORTHORHOMBIC AND ANHYDROUS MONOCLINIC URIC-ACID CRYSTALS [J].
BOISTELLE, R ;
RINAUDO, C .
JOURNAL OF CRYSTAL GROWTH, 1981, 53 (01) :1-9
[4]   Crystallization of monohydrate citric acid. 1. In situ monitoring through the joint use of Raman spectroscopy and image analysis [J].
Caillet, Alexandre ;
Rivoire, Alain ;
Galvan, Jean-Marc ;
Puel, Francois ;
Fevotte, Gilles .
CRYSTAL GROWTH & DESIGN, 2007, 7 (10) :2080-2087
[5]   Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine [J].
Childs, Scott L. ;
Rodriguez-Hornedo, Nair ;
Reddy, L. Sreenivas ;
Jayasankar, Adivaraha ;
Maheshwari, Chinmay ;
McCausland, Linda ;
Shipplett, Rex ;
Stahly, Barbara C. .
CRYSTENGCOMM, 2008, 10 (07) :856-864
[6]   PERSPECTIVES IN SUPRAMOLECULAR CHEMISTRY - FROM MOLECULAR RECOGNITION TOWARDS SELF-ORGANIZATION [J].
LEHN, JM .
PURE AND APPLIED CHEMISTRY, 1994, 66 (10-11) :1961-1966
[7]   High-throughput crystallization:: polymorphs, salts, co-crystals and solvates of phan-naceutical solids [J].
Monissette, SL ;
Almarsson, Ö ;
Peterson, ML ;
Remenar, JF ;
Read, MJ ;
Lemmo, AV ;
Ellis, S ;
Cima, MJ ;
Gardner, CR .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (03) :275-300
[8]   Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation [J].
Nehm, SJ ;
Rodríguez-Spong, B ;
Rodríguez-Hornedo, N .
CRYSTAL GROWTH & DESIGN, 2006, 6 (02) :592-600
[9]  
Rodriguez-Hornedo N., 2005, MOL PHARM, V3, P362
[10]  
RODRIGUEZSPONG B, 2005, THESIS U MICHIGAN